Biogen (NASDAQ:BIIB) Hits New 52-Week High Following Analyst Upgrade

Biogen Inc. (NASDAQ:BIIB) reached a new 52-week high on Monday after JPMorgan Chase & Co. upgraded the stock from a neutral rating to an overweight rating. JPMorgan Chase & Co. now has a $300.00 price target on the stock, up from their previous price target of $210.00. Biogen traded as high as $233.05 and last traded at $235.0730, with a volume of 20,833 shares traded. The stock had previously closed at $225.71.

Several other equities research analysts have also commented on the company. Wedbush upped their price target on Biogen from $201.00 to $215.00 and gave the stock a “neutral” rating in a research note on Thursday, July 30th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Biogen in a research note on Monday, June 22nd. Jefferies Financial Group reaffirmed a “buy” rating on shares of Biogen in a research note on Monday, July 13th. Truist Financial upgraded Biogen from a “hold” rating to a “buy” rating and boosted their target price for the stock from $190.00 to $235.00 in a report on Monday, July 13th. Finally, Oppenheimer reissued an “outperform” rating and set a $300.00 target price on shares of Biogen in a research report on Wednesday, July 29th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $236.04.

Key Stories Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: JPMorgan upgraded Biogen to Overweight from Neutral and raised its price target to $300 from $210. The firm cited an increasingly compelling catalyst path, including expected 2027 clinical readouts for felzartamab and litifilimab. The target implies meaningful upside from recent trading levels. JPMorgan upgrade and price target article
• Positive Sentiment: Litifilimab’s 52-week Phase 2 data in cutaneous lupus erythematosus supported the company’s immunology pipeline. The AMETHYST study showed sustained improvements in skin disease activity and a generally well-tolerated safety profile. FDA Breakthrough Therapy designation further strengthens the drug’s potential, although additional development remains necessary. Litifilimab 52-week data article
• Neutral Sentiment: Citi maintained a Hold rating on Biogen. The stance provides a counterweight to JPMorgan’s upgrade and suggests some analysts believe the recent rally and pipeline optimism may already be reflected in the shares. Citi maintains Hold rating article
• Negative Sentiment: Biogen’s upcoming third-quarter results are expected to show a sharp double-digit EPS decline. This earnings risk is limiting the impact of the bullish pipeline news ahead of the company’s scheduled October 28 report. Biogen quarterly earnings preview article

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of BIIB. BlackRock Inc. purchased a new position in Biogen in the 2nd quarter valued at about $3,453,878,000. Primecap Management Co. CA purchased a new stake in shares of Biogen during the second quarter worth about $3,274,304,000. Legal & General Group Plc purchased a new stake in shares of Biogen during the second quarter worth about $322,640,000. Bank of America Corp DE acquired a new position in shares of Biogen in the second quarter worth about $241,172,000. Finally, Deutsche Bank AG acquired a new position in shares of Biogen in the second quarter worth about $193,165,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Biogen Price Performance

The stock has a market cap of $33.82 billion, a PE ratio of 16.42, a P/E/G ratio of 2.53 and a beta of 0.09. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.87 and a quick ratio of 1.26. The business has a fifty day moving average of $218.37 and a 200 day moving average of $203.00.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.94 by $0.66. The company had revenue of $2.74 billion for the quarter, compared to the consensus estimate of $2.46 billion. Biogen had a return on equity of 11.18% and a net margin of 8.32%. Biogen’s revenue for the quarter was up 3.4% compared to the same quarter last year. During the same period in the previous year, the business earned $5.47 EPS. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Sell-side analysts anticipate that Biogen Inc. will post 12.41 earnings per share for the current year.

About Biogen

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for serious neurological and neurodegenerative diseases. Its research focuses on conditions including multiple sclerosis, spinal muscular atrophy, Alzheimer’s disease, amyotrophic lateral sclerosis and rare neuromuscular disorders.

Biogen’s products include Spinraza (nusinersen) for spinal muscular atrophy, Tysabri (natalizumab) and Tecfidera (dimethyl fumarate) for multiple sclerosis, Qalsody (tofersen) for a genetically defined form of ALS, and Skyclarys (omaveloxolone) for Friedreich’s ataxia.